Dallas, Texas (PRWEB) March 30, 2013
This report provides an overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response. Analysis of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017. Also evaluates technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages. The reports discusses CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others. The report provides patent analysis. And comprehensive company profiles of major players.
Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, indicate what treatment options may be most effective in an individual patient’s case and predict treatment response. They play a role both in new drug R&D and in predicting the outcome of treatment in the medical setting. They are important tools for understanding disease mechanism, developing more effective treatments and improving the quality of patient care.
The report examines the role of CNS biomarkers in early discovery, in drug development and for future diagnostics. The global CNS biomarker market (http://www.reportsnreports.com/reports/70523-central-nervous-system-cns-biomarkers-technologies-and-global-.html) is discussed, and forecasts are made for this segment of the industry for the five-year period from 2012 to 2017. The technological segments of the market (genomic
Copyright©2012 Vocus, Inc.
All rights reserved